Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H34F3N5O3 |
Molecular Weight | 521.5751 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CO)NC1=NC(=CC(=C1)C2=C(C)C=CC(NC(=O)N3CC[C@@H](CC(F)(F)F)C3)=C2)N4CCOCC4
InChI
InChIKey=GZMYLSJUNSCMTD-MOPGFXCFSA-N
InChI=1S/C26H34F3N5O3/c1-17-3-4-21(31-25(36)34-6-5-19(15-34)14-26(27,28)29)13-22(17)20-11-23(30-18(2)16-35)32-24(12-20)33-7-9-37-10-8-33/h3-4,11-13,18-19,35H,5-10,14-16H2,1-2H3,(H,30,32)(H,31,36)/t18-,19+/m1/s1
Molecular Formula | C26H34F3N5O3 |
Molecular Weight | 521.5751 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:34:39 GMT 2023
by
admin
on
Sat Dec 16 18:34:39 GMT 2023
|
Record UNII |
2VPX8HL8AB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
156297592
Created by
admin on Sat Dec 16 18:34:39 GMT 2023 , Edited by admin on Sat Dec 16 18:34:39 GMT 2023
|
PRIMARY | |||
|
12241
Created by
admin on Sat Dec 16 18:34:39 GMT 2023 , Edited by admin on Sat Dec 16 18:34:39 GMT 2023
|
PRIMARY | |||
|
2VPX8HL8AB
Created by
admin on Sat Dec 16 18:34:39 GMT 2023 , Edited by admin on Sat Dec 16 18:34:39 GMT 2023
|
PRIMARY | |||
|
C180835
Created by
admin on Sat Dec 16 18:34:39 GMT 2023 , Edited by admin on Sat Dec 16 18:34:39 GMT 2023
|
PRIMARY | |||
|
2639957-39-2
Created by
admin on Sat Dec 16 18:34:39 GMT 2023 , Edited by admin on Sat Dec 16 18:34:39 GMT 2023
|
PRIMARY | |||
|
300000039591
Created by
admin on Sat Dec 16 18:34:39 GMT 2023 , Edited by admin on Sat Dec 16 18:34:39 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
In contrast to approved therapies targeting Class I V600E BRAF mutant tumors, KIN-2787 was active across all classes of BRAF-altered melanoma cells.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
KIN-2787 is a potent and selective pan-RAF inhibitor that was designed to be effective in all classes of BRAF alterations by targeting mutant BRAF monomers and RAF dimers, regardless of isoform. Furthermore, the pharmacokinetic properties of KIN-2787 allow sustained target coverage, thus minimizing paradoxical activation.
|